EG194588 Activators
Obox7, characterized as an oocyte-specific homeobox gene, stands as a pivotal player in the intricate symphony of embryonic development, particularly in the regulation of transcription by RNA polymerase II. This gene exhibits a multifaceted functionality, predicted to enable DNA-binding transcription factor activity with specificity for RNA polymerase II cis-regulatory regions. The spatial-temporal expression pattern of Obox7 in critical developmental stages, such as the 1-cell and 2-cell embryos, as well as in primary and secondary oocytes, underscores its significance in the orchestration of genetic programs governing early embryogenesis. The envisaged role of Obox7 in the transcriptional regulation by RNA polymerase II suggests its involvement in the intricate choreography of gene expression that ultimately shapes the developmental fate of oocytes and embryos.
Inhibition of Obox7 is achieved through a diverse array of mechanisms, each influencing its function either directly or indirectly. Direct inhibitors, exemplified by Actinomycin D and α-Amanitin, exert their effects by disrupting the interaction between Obox7 and RNA polymerase II. These inhibitors interfere with the intricate process of transcription, hindering Obox7's ability to bind specifically to cis-regulatory regions. On the other hand, indirect inhibitors, such as 5-Fluorouracil and Camptothecin, impact nucleotide metabolism and DNA topology, affecting Obox7 in a broader cellular context. These mechanisms indirectly compromise Obox7's function in the regulation of transcription by RNA polymerase II. The diversity of inhibitory mechanisms illustrates the intricacy of Obox7's regulatory network, emphasizing its susceptibility to perturbations in essential cellular processes that extend beyond its immediate DNA-binding activity. Understanding the nuanced interplay between Obox7 and its inhibitors contributes to a deeper comprehension of the molecular dynamics governing early embryonic development and sheds light on potential avenues for targeted interventions in gene regulatory pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits Obox7 by intercalating into DNA, preventing RNA polymerase II binding. This interference disrupts transcriptional regulation, directly inhibiting Obox7's DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits Obox7 by blocking RNA polymerase II activity. This inhibition disrupts transcriptional processes, directly impacting Obox7's predicted involvement in the regulation of transcription by RNA polymerase II. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil inhibits Obox7 indirectly by affecting nucleotide synthesis. As an antimetabolite, it disrupts cellular processes, indirectly inhibiting Obox7's DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits Obox7 indirectly by targeting DNA topoisomerase I. This disruption in DNA topology indirectly impacts Obox7's transcriptional regulation, inhibiting its DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
6-Thioguanine | 154-42-7 | sc-205587 sc-205587A | 250 mg 500 mg | $42.00 $54.00 | 3 | |
Thioguanine inhibits Obox7 by interfering with nucleotide metabolism. This indirect inhibition disrupts cellular processes, impacting Obox7's DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits Obox7 indirectly by targeting DNA topoisomerase II. This disruption in DNA topology indirectly impacts Obox7's transcriptional regulation, inhibiting its DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $72.00 $104.00 | ||
6-Mercaptopurine inhibits Obox7 indirectly by affecting nucleotide metabolism. This disruption in cellular processes indirectly inhibits Obox7's DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin inhibits Obox7 indirectly by causing DNA damage. This disruption in DNA structure indirectly impacts Obox7's transcriptional regulation, inhibiting its DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid inhibits Obox7 by targeting inosine monophosphate dehydrogenase. This indirect inhibition affects nucleotide synthesis, disrupting Obox7's DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C inhibits Obox7 indirectly by inducing DNA cross-linking. This disruption in DNA structure indirectly impacts Obox7's transcriptional regulation, inhibiting its DNA-binding transcription factor activity and cis-regulatory region binding. | ||||||